MGNX vs RNA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MGNX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company shows explosive revenue growth (113% YoY) and maintains a strong liquidity position (Current Ratio 5.10), it suffers from negative gross margins and a consistent track record of missing earnings estimates. The recent 1-year price surge appears decoupled from fundamental value, as the company remains deeply unprofitable with a catastrophic ROE of -86.94%.
RNA exhibits critical financial distress, characterized by a Piotroski F-Score of 4/9 which barely maintains a 'stable' rating despite catastrophic liquidity metrics. The company is facing a severe solvency crisis with a Current Ratio of 0.07 and a negative Price/Book ratio of -3.57, indicating negative shareholders' equity. Revenue has collapsed by 71.10% YoY, and the company has missed earnings estimates in 100% of the last four quarters. Combined with aggressive insider selling by the CEO and CFO, the fundamental outlook is extremely poor.
Compare Another Pair
Related Comparisons
MGNX vs RNA: Head-to-Head Comparison
This page compares MacroGenics, Inc. (MGNX) and Atrium Therapeutics, Inc. (RNA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.